AnodyneWiki

Neostigmine

Neostigmine
Neostigmine
Salts
[]
Neostigmine mesylate
Neostigmine mesylate
Molecular structure drawn from PubChem coordinates
Physical properties
[]
Molecular mass223.29 g/mol [1]
Solubility6.77e-02 g/L [1]
Predicted LogP1.5 [1]
Structural Identifiers
[]
Molecular formulaC12H19N2O2+
IUPAC name[3-(dimethylcarbamoyloxy)phenyl]-trimethylazanium
SMILESCN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C
InChIInChI=1S/C12H19N2O2/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5/h6-9H,1-5H3/q+1
InChIKeyALWKGYPQUAPLQC-UHFFFAOYSA-N
CAS number59-99-4
UNII3982TWQ96G
PubChem CID4456
Pharmacokinetics[]
OnsetWithin 10-20 min (injection), with 4 hrs (by mouth)
Elimination half-life50–90 minutes
Duration of actionup–4 hours
MetabolismSlow hydrolysis by acetylcholinesterase and also by plasma esterases
ExcretionUnchanged drug (up to 70%) and alcoholic metabolite (30%) are excreted in the urine
Routes of administrationIntramuscular, intravenous, subcutaneous, by mouth

Neostigmine (also known as Eustigmine, Eustigmin, Prostigmine, Vagostigmine, Prostigmin, Juvastigmin, Neostigmin, Synstigmin, m-Trimethylammoniumphenyldimethylcarbamate or 3-Trimethylammoniumphenyl N,N-dimethylcarbamate) is a substance of the aniline class.

Chemistry

Salts []

Neostigmine is typically found in the form of its mesylate salt.

 []

Neostigmine is achiral.

Neostigmine matches Lipinski's rule of five.

Pharmacology

Mechanism of action []

Neostigmine is a parasympathomimetic, specifically, a reversible cholinesterase inhibitor. The drug inhibits acetylcholinesterase which is responsible for the degredation of acetylcholine. So, with acetylcholinesterase inhibited, more acetylcholine is present By interfering with the breakdown of acetylcholine, neostigmine indirectly stimulates both nicotinic and muscarinic receptors which are involved in muscle contraction.. It does not cross the blood-brain barrier. [1]

Interactions []

Interaction mechanisms documented in (number of interacting drugs):

shared target16

Medical side effects []

70 side effects listed on drug labels in (neostigmine).

  • Anaphylactic shock
  • Arrhythmia
  • Arthralgia
  • Musculoskeletal discomfort
  • Asthenia
  • Atrioventricular block
  • Bronchospasm
  • Cardiovascular disorder
  • Connective tissue disorder
  • Diarrhoea
  • Somnolence
  • Dysarthria
  • Slurred speech
  • Osteoarthritis
  • Dermatitis
  • Rash
  • Muscle contractions involuntary
  • Flatulence
  • Flushing
  • Gastrointestinal disorder
  • Cardiac arrest
  • Hypersensitivity
  • Hypotension
  • Mediastinal disorder
  • Miosis
  • Muscle spasms
  • Nervous system disorder
  • Abnormal behaviour
  • Convulsion
  • Dizziness
  • Shock
  • Syncope
  • Loss of consciousness
  • Pollakiuria
  • Urethral disorder
  • Urinary tract disorder
  • Urticaria
  • Respiratory arrest
  • Nodal rhythm
  • Respiratory depression
  • Pulmonary function test decreased
  • Hyperhidrosis
  • Gastrointestinal pain
  • Abdominal pain
  • Mental disorder
  • Coma
  • Dyspnoea
  • Headache
  • Nausea
  • Nystagmus
  • Pruritus
  • Salivary hypersecretion
  • Tachycardia
  • Urinary incontinence
  • Vomiting
  • Wheezing
  • Dry mouth
  • Agitation
  • Skin disorder
  • Chest discomfort
  • Lacrimation increased
  • Bradycardia
  • Paralysis
  • Laryngeal pain
  • Insomnia
  • Procedural complication
  • Incision site complication
  • Procedural nausea
  • Procedural pain
  • Post procedural complication

Indications

  • Distention
  • Dysphagia
  • Intestinal atony
  • Myasthenia gravis
  • Urinary retention

 []

  • Australia: Neostigmine is a Schedule 4.
  • United Kingdom: Neostigmine is Prescription only.
  • United States: Neostigmine is Prescription only.[3]

See also []

External links []

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 4456, Neostigmine. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/4456
  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Neostigmine. UNII: 3982TWQ96G. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/3982TWQ96G
  3. Bloxiverz- neostigmine methylsulfate injection. DailyMed. 3 March 2021. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1fb5c812-1e63-4bd9-a68e-7f9dc5e7a33a

Data sources []

SourceStatusUpdated (UTC)
dosingmissing (no dosing statistics)2026-11-20 20:01:59
drugspromissing (no DrugsPRO reagent data)2026-11-20 20:01:54
erowidmissing (no Erowid substance of that name)2026-11-20 20:01:54
gsrsok2026-11-20 20:01:56
hmdbmissing (hmdb.ca refused automated access to HMDB0015472)2026-11-20 20:01:54
keggok2026-11-20 20:01:57
pubchemok2026-11-20 20:01:54
redditmissing (no r/tripreports posts mention it)2026-11-20 20:01:54
siderok2026-11-20 20:01:55
structureok2026-11-20 20:01:54
wikipediaok2026-11-20 20:01:55